How Are Label-Free Technologies Used in Early Drug Discovery?
Most small molecule drugs and biologics, including monoclonal antibodies, interact with a therapeutic target to alter its function. Traditional analytical techniques such as fluorescence-based assays involve tagging analytes or secondary reagents with a fluorescent moiety. Labeling is typically not site-specific and can lead to structural alterations that may affect its activity. Data quality issues can also arise due to interference from fluorescent labels.
Modern analytical techniques designed for real-time analysis and high-throughput capabilities significantly reduce the time taken to discover promising therapeutics with the best chances for success downstream.
Download this eBook to learn about label-free solutions that:
- Reduce the time it takes to identify, select and optimize drug candidates
- Allow for high-throughput target specificity analysis
- Facilitate the selection of clones less likely to fail downstream
